Plain-English translation of NCT06441812 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing SHR-1703, a new injectable medication designed to help people with eosinophilic asthma—a specific type of asthma where certain white blood cells called eosinophils are too high and cause breathing problems. Researchers want to understand whether this medication is safe to use long-term and whether it helps control asthma symptoms better. The study will follow about 200 people over time to see how the medication works.
Many people with eosinophilic asthma continue to have asthma attacks and breathing problems even when taking strong controller medicines. Researchers are testing this medication to see if it can offer better control for patients who are struggling despite their current treatments.
You likely qualify if…
You likely don't qualify if…
You would receive injections of the new medication under your skin at regular visits over a period of months. During the study, you'll have blood tests, breathing tests, and check-ins with the research team to monitor how well the medication works and check for any side effects. The study tracks your asthma symptoms, how often you need rescue inhalers, and changes in your lung function to see if the medication helps you breathe better and have fewer asthma attacks.
AI-generated summary from trial data · Jun 29, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Guangdong Hengrui Pharmaceutical Co., Ltd
Enrollment target
~200 participants
Started
July 2024
Primary completion
September 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Tianqi Zheng
Guangdong Hengrui Pharmaceutical Co., Ltd
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.